Lexicon Pharmaceuticals traded at $1.98 this Tuesday June 2nd, decreasing $0.09 or 4.35 percent since the previous trading session. Looking back, over the last four weeks, Lexicon Pharmaceuticals lost 23.75 percent. Over the last 12 months, its price rose by 213.29 percent. Looking ahead, we forecast Lexicon Pharmaceuticals to be priced at 2.14 by the end of this quarter and at 2.01 in one year, according to Trading Economics global macro models projections and analysts expectations.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.